Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, March 2008, p. 1159-1161, Vol. 52, No. 3
0066-4804/08/$08.00+0 doi:10.1128/AAC.01101-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

David Taylor,2
Deborah Middleton,3
Robert W. Milne,4
Kingsley Coulthard,4,5 and
John D. Turnidge6
Facility for Anti-infective Drug Development and Innovation,1 Department of Pharmaceutical Biology, Victorian College of Pharmacy, Monash University, Parkville, Melbourne, Victoria 3052,2 CSIRO Australian Animal Health Laboratory, East Geelong, Victoria 3220,3 Sansom Institute, School of Pharmacy and Medical Science, University of South Australia, Adelaide, South Australia 5000,4 Department of Pharmacy,5 Division of Laboratory Medicine, Women's and Children's Hospital, North Adelaide, South Australia 5006, Australia6
Received 22 August 2007/ Returned for modification 15 October 2007/ Accepted 25 December 2007
The relative nephro- and neurotoxicity of colistin methanesulfonate (CMS) was investigated with rats during 7 days of intravenous administration in regimens mimicking twice- and once-daily dosing of a clinically relevant dose for humans. Histological examination revealed more-severe renal lesions with the regimen corresponding to once-daily dosing, indicating that the potential for renal toxicity may be greater with extended-interval dosing.
Published ahead of print on 7 January 2008.
Present address: F. Hoffman-La Roche Ltd., Pharmaceuticals Division, Basel, Switzerland.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»